Compare BRID & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | BYSI |
|---|---|---|
| Founded | 1932 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 58.4M |
| IPO Year | 1995 | 2016 |
| Metric | BRID | BYSI |
|---|---|---|
| Price | $7.44 | $1.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.0K | ★ 19.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $174,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $7.00 | $0.98 |
| 52 Week High | $10.40 | $3.44 |
| Indicator | BRID | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 60.62 |
| Support Level | $7.41 | $1.38 |
| Resistance Level | $8.10 | $1.81 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 58.44 | 78.37 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.